European Union: Healthcare

The European Union has spent the last decade reshaping the digital regulatory landscape through landmark legislation such as the General Data Protection Regulation (GDPR) and the AI Act. The European Health Data Space (EHDS) Regulation is the next significant step in that evolution. While often described as a healthcare initiative, the EHDS is at its core a data governance framework designed to unlock the value of electronic health data while safeguarding fundamental rights and promoting innovation.

The Belgian Federal Agency for Medicines and Health Products has issued comprehensive new guidance on pharmaceutical promotion to healthcare professionals, consolidating previous circulars and introducing stricter...

Greenberg Traurig attorneys explore the complexities of entering the European healthcare market, examining how the EU's conformity-based regulatory system differs from the FDA model and why product classification decisions can make or break market entry.

Effective service date for an unrepresented defendant who did not yet make an appearance in court is calculated under R. 271.6.b RoP, subject to the “unless” conditions of that rule.

Gérard Haas et son équipe ont compilé les actualités juridiques numériques les plus marquantes de la semaine, couvrant les alertes d'Anthropic sur l'auto-amélioration récursive de l'IA, les nouvelles sanctions de la DGCCRF contre SHEIN, les risques liés aux chatbots d'intimité, les inquiétudes autour de Doctolib et des données de santé, ainsi que la nouvelle stratégie open source européenne.

Healthcare services around the world are coming under increasing pressure as lengthening life expectancies and aging populations drive patient demand ever higher.

The access conditionality under Article 56a has shifted from an incentive (“carrot”) to a penalty (“stick”) — Member States can request marketing authorization holders (MAH) to launch and supply products...

On 20 April 2026, the Dutch government published a draft Implementation Act setting out the national governance structure for AI supervision under the AI Act.

João Taborda da Gama continues to shape international discourse on psychedelic regulation, speaking at major European forums on the legal, ethical, and philosophical tensions surrounding controlled substances. His recent presentations in Ukraine and Portugal examine who holds authority over consciousness-altering therapies, whether existing frameworks reflect coherent principles or accumulated habit, and what risks and possibilities fall outside medicalization's reach.